Journal article
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
Diabetes, metabolic syndrome and obesity, Vol.3, pp.215-226
07/14/2010
Handle:
https://hdl.handle.net/2376/113858
PMCID: PMC3047975
PMID: 21437090
Abstract
Liraglutide is a glucagon-like peptide-1 analog with pharmacokinetic properties suitable for once-daily administration approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes. Clinical trial data from large, controlled studies demonstrate the safety and efficacy of liraglutide in terms of hemoglobin A
1c
(HbA
1c
) reduction, reductions in body weight, and the drug’s low risk for hypoglycemic events when used as monotherapy. Liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative data with insulin glargine and exenatide therapy are available from Phase III trials. Once-daily administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, with similar improvements in HbA
1c
and body weight observed when liraglutide was compared with exenatide. The glucose-dependent mechanism of insulin release with incretin analog therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia when used with non-secretagogue medications. Data to date on patient-reported outcomes with liraglutide treatment are encouraging. The most common adverse events associated with liraglutide therapy are dose-dependent nausea, vomiting, and diarrhea. Diligent postmarketing surveillance to elucidate the risk of pancreatitis and medullary thyroid carcinoma in a heterogeneous population are likely warranted.
Metrics
8 Record Views
Details
- Title
- Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
- Creators
- Joshua J Neumiller - Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WashingtonTravis E Sonnett - Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USALindy D Wood - Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WashingtonStephen M Setter - Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, WashingtonR Keith Campbell - Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USA
- Publication Details
- Diabetes, metabolic syndrome and obesity, Vol.3, pp.215-226
- Academic Unit
- Pharmacotherapy, Department of
- Publisher
- Dove Medical Press
- Identifiers
- 99900548316301842
- Language
- English
- Resource Type
- Journal article